LSE

Publication of the Prospectus and Circular

Retrieved on: 
Monday, December 25, 2023
LSE, Bank Holding Company Act, Mass meeting, BANK, Prospectus, A4200 road, London Stock Exchange, Annual general meeting, Official List, ANY, METRO, FCA, Proxy, Cryptocurrency

Metro Bank Holdings PLC (LSE: MTRO LN)

Key Points: 
  • Metro Bank Holdings PLC (LSE: MTRO LN)
    NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
  • The Prospectus contains a Notice of General Meeting, which will be held at One Southampton Row, London WC1B 5HA on 27 November at 11.30am.
  • The Prospectus has been approved by the FCA and, together with a form of proxy relating to voting at the General Meeting, is available on the Company’s website at: www.metrobankonline.co.uk/investor-relations .
  • Terms used in this announcement shall, unless the context otherwise requires, be as defined in the Prospectus.

Fix Price Group PLC comments on investors’ questions about redomiciliation

Retrieved on: 
Friday, December 22, 2023
AIX, Moscow Exchange, London Stock Exchange, Human, Fix Price, LSE, MOEX, Cryptocurrency, GDR

28 November 2023 – Fix Price Group PLC (LSE and MOEX: FIXP, AIX: FIXP.Y, “Fix Price”, the “Company” or the “Group”), one of the leading variety value retailers globally and the largest in Russia, acknowledges that it has received questions and concerns from investors in the context of its upcoming redomiciliation to Kazakhstan.

Key Points: 
  • 28 November 2023 – Fix Price Group PLC (LSE and MOEX: FIXP, AIX: FIXP.Y, “Fix Price”, the “Company” or the “Group”), one of the leading variety value retailers globally and the largest in Russia, acknowledges that it has received questions and concerns from investors in the context of its upcoming redomiciliation to Kazakhstan.
  • Pursuant thereto, Fix Price confirms the position described in its press release of 9 October 2023 , whereby it intends to maintain its current Global Depositary Receipts (GDR) programme and its GDR listing on the London Stock Exchange, Moscow Exchange and the Astana International Exchange following the proposed redomiciliation.
  • The Company confirms that it is not currently planning to buy back or exchange its GDRs.
  • Fix Price is also exploring possible options for paying out dividends to all shareholders, given the current regulatory environment.

Chair succession

Retrieved on: 
Thursday, December 21, 2023
Clarkson plc, Venture, Senior, Audit, GRW, LSE, Atom Bank, Investment, Committee, Cazenove, Environment, Interim, Vice, Valuation, Equity capital markets, Euronext Dublin, JPMorgan Chase, Risk, Management

Laurence will also Chair the Nomination Committee and become a member of the Remuneration Committee.

Key Points: 
  • Laurence will also Chair the Nomination Committee and become a member of the Remuneration Committee.
  • Grahame Cook will resume his role as Senior Independent Director and Chair of the Audit, Risk and Valuations Committee following an orderly handover.
  • He is currently chair of Clarkson plc, the world’s largest shipbroker, and a non-executive director of Atom Bank plc, an online retail challenger bank.
  • Grahame Cook, Interim Chair of Molten Ventures, commented:
    “The Board is delighted to welcome Laurence to Molten.

PDMR dealings

Retrieved on: 
Thursday, December 21, 2023
London Stock Exchange, Stock, SEM, MUR, Stock exchange, LSE, FCA, Mauritians, USD, Security (finance)

These high-quality assets are underpinned by predominantly US$ and Euro denominated long-term leases with a wide range of blue-chip multi-national tenant covenants across a diverse range of robust property sectors.

Key Points: 
  • These high-quality assets are underpinned by predominantly US$ and Euro denominated long-term leases with a wide range of blue-chip multi-national tenant covenants across a diverse range of robust property sectors.
  • The Company is committed to delivering strong and sustainable income for shareholders, with the potential for income and capital growth.
  • SEM authorised representative and sponsor: Perigeum Capital Ltd
    This notice is issued pursuant to the FCA Listing Rules, SEM Listing Rules 15.24 and the Mauritian Securities Act 2005.
  • The Board of the Company accepts full responsibility for the accuracy of the information contained in this communiqué.

Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial

Retrieved on: 
Thursday, December 21, 2023
Patient, Uveal melanoma, Biotechnology, Compass, Life, Radiation, Safety, LSE, Paratriathlon, Pharmaceutical industry, Online shopping, Aura

LONDON, 8 December 2023: Arix Bioscience plc (“Arix”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Aura Biosciences (“Aura”) (NASDAQ: AURA) has announced that the first patient has been dosed in the global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma.

Key Points: 
  • LONDON, 8 December 2023: Arix Bioscience plc (“Arix”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Aura Biosciences (“Aura”) (NASDAQ: AURA) has announced that the first patient has been dosed in the global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma.
  • Arix holds 1,508,483 shares in Aura.
  • The holding value of these shares will continue to be determined by the market price of Aura’s shares.
  • Robert Lyne, CEO of Arix, commented: “We are pleased to see Aura reach this major milestone and progress into phase 3 trials.

MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member

Retrieved on: 
Thursday, November 16, 2023
Disease, Biotechnology, Patient, LSE, Vaccine, Messenger, Health, Therapy, Conference, AMM, Transfection, Public, RNA

AMM is the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health and society.

Key Points: 
  • AMM is the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health and society.
  • AMM’s mission is to propel the future of mRNA medicines, improve patients’ lives, and advance scientific knowledge by convening and empowering mRNA industry leaders, innovators, scientists and other key stakeholders.
  • MaxCyte is one of 31 founding members comprised of biotechnology, biopharma and life sciences companies and educational institutions.
  • “We proudly join our colleagues in advancing AMM’s mission as we recognize the significant potential of mRNA scientific innovation to transform human health,” said Doug Doerfler, President and CEO of MaxCyte.

Canadian General Investments, Limited Announces Additional Independent Directors

Retrieved on: 
Wednesday, November 15, 2023
TD Securities, Investment, LSE, PwC, Soulpepper, Investment banking, TSX

Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The Board of Directors of Canadian General Investments, Limited (TSX:CGI) (LSE:CGI) is pleased to announce the appointment of Sanjay Nakra as an independent director to the Board.

Key Points: 
  • Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The Board of Directors of Canadian General Investments, Limited (TSX:CGI) (LSE:CGI) is pleased to announce the appointment of Sanjay Nakra as an independent director to the Board.
  • Mr. Nakra joins independent director Michael Walke, who was elected to the Board at the Corporation’s Annual General Meeting in April, as the two newest Directors.
  • He presently serves as the CEO of the Canadian Centre for Audit Quality (CCAQ), an independent, non-profit corporation established in 2021 dedicated to advancing confidence in Canada’s public accounting and auditing profession.
  • Established in 1930 and listed in Toronto and London, Canadian General Investments is a closed-end equity fund focussed on medium- to long-term investments in primarily Canadian corporations.

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

Retrieved on: 
Tuesday, November 14, 2023
Chronic kidney disease, Research, Telephone, Joslin Diabetes Center, Senior, GMT, Kidney disease, PIN, American Diabetes Association, Insurance, Patient, LSE, Calendar, FDA, Type 2 diabetes, PPO, Marketing, CMS, EGFR, Biomarker, Hospital, A1C, Physician, Diabetes, Patent, Medical device, Pharmaceutical industry, Health insurance, Cryptocurrency

During the three months ended September 30, 2023, the Company recognized $0.5 million of revenue, compared to $1.0 million for the three months ended September 30, 2022.

Key Points: 
  • During the three months ended September 30, 2023, the Company recognized $0.5 million of revenue, compared to $1.0 million for the three months ended September 30, 2022.
  • Cost of revenue for the three months ended September 30, 2023 was $0.5 million, compared to $0.7 million for the three months ended September 30, 2022.
  • Operating expenses for the three months ended September 30, 2023 was $8.8 million, compared to $12.0 million for the three months ended September 30, 2022.
  • Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman

Retrieved on: 
Tuesday, November 14, 2023
HM, Albireo, Therapy, Notifiable disease, Biotechnology, LSE, Arrow, Cambridge Antibody Technology, Science, CAT, London Stock Exchange, Cellular senescence, RNA, OBE, Pharmaceutical industry, Management

SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman

Key Points: 
  • SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman
    Exeter, UK — 14 November 2023: SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and treat age-related disease, today announces the appointment of Dr. David Chiswell Ph.D, OBE as Chairman of the Board.
  • Dr. Chiswell has served as the Chairman of the Board of various biotechnology companies including Albireo, Arrow and Sosei.
  • Dr. Sarah Cole, CEO of SENISCA, commented: “We are honoured to welcome Dr. Chiswell to our Board at SENISCA.
  • I am thrilled to be joining the Company as Chairman, and I look forward to collaborating with the Board and leadership team as SENISCA progresses into the next stage of its development.”

KBRA Publishes Long-Term Credit Rating of A- with a Stable Outlook for Helios Underwriting plc's Series A Senior Unsecured Notes

Retrieved on: 
Friday, December 15, 2023
Professional Services, Finance, ESG, Risk, Growth, Note, KBRA, Outlook, LSE, HUW, Limited, Bank, Telescopic sight, Helios

KBRA publishes the long-term credit rating of A- assigned to Helios Underwriting plc’s 9.5% fixed rate USD 75 million Series A Senior Unsecured Notes due December 15, 2030.

Key Points: 
  • KBRA publishes the long-term credit rating of A- assigned to Helios Underwriting plc’s 9.5% fixed rate USD 75 million Series A Senior Unsecured Notes due December 15, 2030.
  • The Outlook for the rating is Stable.
  • On November 14, 2023, KBRA initially assigned an unpublished A- preliminary long-term credit rating with a Stable Outlook.
  • Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at www.kbra.com.